1 / 4

IVD Antibody Development Services for CK20 Marker

In vitro diagnostics (IVD) antibodies are considered as a useful and sensitive tool in the diagnosis of diseases for monitoring drug therapies or determining prognosis after surgeries.

bellasmith12
Télécharger la présentation

IVD Antibody Development Services for CK20 Marker

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IVD Antibody Development Services for CK20 Marker In vitro diagnostics (IVD) antibodies are considered as a useful and sensitive tool in the diagnosis of diseases for monitoring drug therapies or determining prognosis after surgeries. As a well-known leader in IVD market, Creative Biolabs devotes to launching a broad range of IVD antibodies and services for diverse diseases, especially in colorectal cancer. Cytokeratin and CK20 Cytokeratin (CK) belongs to one of the intermediate filaments and is subdivided into cytokeratins and hair keratin. It is a member of among approximately twenty cytoskeletal structural proteins present in normal epithelial cells and responsible for the structural integrity of epithelium. The expression of CK is maintained during the malignant transformation, which is a powerfully useful tool in oncology diagnostics. Since CK expression is often preserved in tumorous cells, the application of specific antibodies is valuable in determining the origin of metastatic carcinomas. Fig.1 Normal colonic epithelium with cytokeratin 20 (A) and cytokeratin 7 (B) immunoreactivity (Note: The lack of CK7 immunoreactivity in neoplastic gland) (100×). (Bayrak, R., 2011) CK20 (Cytokeratin 20) is an intermediate filament protein with 46 kDa. It is a low molecular weight member of the CK protein family, which is restricted to express in gastric and intestinal epithelial cells, urothelium, and Merkel cells, as well as in primary colorectal carcinomas and their metastases. Essentially, CK20 is non-reactive in squamous cell cancers, adenocarcinomas of lungs,

  2. breasts, and endometria, and non-mucinous tumors of ovaries and small cell carcinomas. CK20 has been identified as a unique type I cytokeratin. The type I keratin consists of acidic proteins arranged in pairs of heterotypic keratin chains and its gene is clustered in a region of chromosome 17q12-q21. CK- based tumor biomarker tests may be recognized as simple, cheap, noninvasive, and reliable predictive methods and offer a sight for more efficient management compared to conventional approaches. CK20 and CRC Colorectal carcinoma (CRC) remains one of the major cancer-related deaths despite some progress of treatments gained last years. Detection of this disease at earlier stages can reduce its mortality to large extent. Higher expression level of CK20 in patients maybe is regarded as a promising sign for the diagnosis of diseases in non-metastatic stages. Current data suggest that the identification of CK20 as relative sensitive markers has potential to be of value choice for primary diagnosis of CRC in early phases. The correlations between the expression level of CK20 and efficacy of CRC treatment and postoperative prognosis are evaluated to demonstrate the clinical value of CK20. Postoperative follow-up is performed on 62 patients who have undergone surgery for CRC in two years. The collected specimens are tumor tissues and intraperitoneal drainage fluids of these patients, together with blood samples during the two-year follow-up period. The relationship between the CK20 levels and postoperative outcomes is analyzed by Spearman correlation analysis. Both in tumor samples and intraperitoneal drainage fluids, CK20 levels are lower in patients with earlier stages than in those at later stages. During postoperative follow-up, patients with serum negative CK20 have significantly higher three-year survival rates than serum positive CK20 patients. CK20 expressions can provide valuable clinic information on the postoperative prognosis of CRC patients.

  3. Fig.2 Immunohistochemical analyses of CK20 expression in tumor tissues. (Cayrefourcq, L., 2015) CK20 IVD Antibody for CRC CRC is one of the most common malignant tumors with a three-year survival rate of approximately 70% after surgical resection. There still is a trend to increase mortality, though modern cancer therapeutics can manage and control the progression of CRC effectively. Currently, techniques for the CRC evaluation include observation of clinical symptoms, pathological examination and tumor marker level measurement. However, they are all appearing inherent limitations that lead to challenging in detecting early stage carcinomas and lymph node metastases. The considerable progress has been achieved towards improving survival of patients. Because more than 60% of CRC is identified at the symptomatic phases with a lower rate of long-term survival, so thus, it is critical to diagnose the cancer indication at the earlier asymptomatic stages with effective screening. By evaluating mRNA expression of specific tumor markers, cancer cells can be detected in peripheral blood of cancer patients compared with healthy controls. The reason is that the tumor cells shed from the primary carcinoma mass into the bloodstream can be tracked in the early phases of the disease. Lots of tumor markers, such as CK20, have been revealed to be stable and specifically expressed in primary and metastatic CRC and have been picked for the efficient detection of circulating cancer cells in peripheral

  4. blood. Creative Biolabs is an expert at in vitro diagnostics (IVD) development service and we can offer IVD antibodies for colorectal cancer to target CK20. Except that, there is a wide range of IVD products provided in Creative Biolabs. Please contact us for more detailed information. References 1. Bayrak, R., (2011). “Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas.”Pathol Res Pract, 207(3), 156-160. 2. Cayrefourcq, L., (2015). “Establishment and characterization of a cell line from human circulating colon cancer cells.”Cancer research, 75(5), 892-901. Related Services: IVD Antibody Development Services for Carcinoembryonic Marker IVD Antibody Development Services for CK18 Marker IVD Antibody Development Services for CA 72-4 Marker IVD Antibody Development Services for CA 11-19 Marker IVD Antibody Development Services for CDC25B Phosphatase Marker IVD Antibody Development Services for Ezrin Marker IVD Antibody Development Services for CD166 Marker IVD Antibody Development Services for ABCG5 Marker IVD Antibody Development Services for Nucleosome Marker

More Related